Evidence map›Paper›PMID 35403152›Full record

ArticleCancer diagnosis & prognosis

Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel.

Wataru Izumo, Ryota Higuchi, Toru Furukawa, Takehisa Yazawa, Shuichiro Uemura, Yutaro Matsunaga, Masahiro Shiihara, Masakazu Yamamoto

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wataru IzumoDepartment of Surgery, Institute of Gastroenterology, Tokyo Woman's Medical University, Tokyo, Japan.
Ryota HiguchiDepartment of Surgery, Institute of Gastroenterology, Tokyo Woman's Medical University, Tokyo, Japan.
Toru FurukawaDepartment of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takehisa YazawaDepartment of Surgery, Institute of Gastroenterology, Tokyo Woman's Medical University, Tokyo, Japan.
Shuichiro UemuraDepartment of Surgery, Institute of Gastroenterology, Tokyo Woman's Medical University, Tokyo, Japan.
Yutaro MatsunagaDepartment of Surgery, Institute of Gastroenterology, Tokyo Woman's Medical University, Tokyo, Japan.
Masahiro ShiiharaDepartment of Surgery, Institute of Gastroenterology, Tokyo Woman's Medical University, Tokyo, Japan.
Masakazu YamamotoDepartment of Surgery, Institute of Gastroenterology, Tokyo Woman's Medical University, Tokyo, Japan.
Tokyo Women's Medical University · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gemcitabine together with nab-paclitaxel (GnP) has been shown to improve outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). However, the predictive markers for treatment effects remain unclear. This study aimed to identify early prognostic factors in patients with PDAC receiving GnP. Patients and Methods: We analyzed 113 patients who received GnP for PDAC and evaluated the relationship between clinical factors and outcomes. Results: The median survival time (MST) was 1.2 years. In multivariate analysis, baseline carbohydrate antigen 19-9 (CA19-9) ≥747 U/ml [hazard ratio (HR)=1.9], baseline controlling nutrition status (CONUT) score ≥5 (HR=3.7) and changing rate of CA19-9 after two GnP cycles ≥0.69 (HR=3.7) were independent risk factors for poor prognosis. When examining outcomes according to pre-chemotherapeutic measurable factors (baseline CA19-9 and CONUT), the MSTs of patients with pre-chemotherapeutic zero risk factors (pre-low-risk group, n=63) and one or more risk factors (pre-high-risk group, n=50) were 1.7 and 0.65 years (p<0.001), respectively. The MST for those with a changing rate of CA19-9 after two GnP cycles <0.69 and ≥0.69 was significantly different in both groups (2.0 and 1.2 years in the pre-low-risk group, p<0.001; 1.0 and 0.52 years in the pre-high-risk group, p<0.001). Conclusion: These results may be useful for decision-making regarding treatment strategies in patients with PDAC receiving GnP.

Indexed as

CA19-9 antigenchemotherapynutrition statuspaclitaxelrisk factors

Identifiers

PMID35403152
PMCPMC8962866
OpenAlexW3211708282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.